Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, conjugated oestrogens/bazedoxifene (Duavive®) cannot be endorsed for use within NHS Wales for the treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate. |
||
|
||
Medicine details |
||
| Medicine name | conjugated oestrogens / bazedoxifene (Duavive®) | |
| Formulation | 0.45 mg/20 mg modified-release tablet | |
| Reference number | 1511 | |
| Indication | Treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate |
|
| Company | Pfizer Ltd | |
| BNF chapter | Endocrine system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 15/05/2015 | |